Epizyme Widens Q2 Loss, Revenues Decline YoY
7:15AM ET 8/09/2019 MT NewswiresEpizyme (EPZM), a biopharmaceutical company, reported Friday Q2 net loss of $0.53 per share compared with the $0.42 loss per share in the prior year period...
Quotes Snapshot > EPZM
Epizyme Inc EPZM:NASDAQ
Last Price$12.19NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/16/19
NASDAQ 15-minute delayed Bid/Ask Quotes
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$11.70 (5)
Ask (Size)$12.88 (20)
Day Low / HighN/A - N/A
Volume953.0 K
Read more news Recent News
Epizyme Names Tombesi as CFO
1:13PM ET 7/22/2019 MT NewswiresEpizyme (EPZM) said on Monday it has appointed Paolo Tombesi, former finance head at Insmed, as its CFO starting next month. Epizmye said that Tombesi...
Insider Trends: Insider Prolongs Selling Trend at Epizyme
7:07PM ET 6/28/2019 MT NewswiresDavid M Mott, Director, on Jun 27, 2019, sold 52,473 shares in Epizyme (EPZM) for $652,134. Mott, following the transactions delineated in the Form 4 SEC...
Epizyme Reports Positive Interim Data From Trial of Lymphoma Drug
9:06AM ET 6/21/2019 MT NewswiresEpizyme (EPZM) on Friday reported positive interim data from an ongoing phase 2 trial of the company's lead candidate, tazemetostat, as a monotherapy for...
View all Commentary and Analysis
Week 34 Breakout Forecast: Short-Term Picks To Give You An Edge
6:28AM ET 8/18/2019 Seeking AlphaEpizyme's NDA Filing Acceptance Moves It Forward Toward New Territory
2:17PM ET 8/12/2019 Seeking AlphaForensic Stock Analysis For August: Do You Own These Stocks?
3:02PM ET 8/02/2019 Seeking AlphaEpizyme: A Promising Long-Term Pick For The Healthcare Investor
6:58AM ET 7/20/2019 Seeking AlphaCompany Profile
Business DescriptionEpizyme, Inc. is a clinical-stage biopharmaceutical company, which engage in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. It also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. View company web site for more details
| Address | 400 Technology Square Cambridge, Massachusetts 02139 |
| Phone | +1.617.229.5872 |
| Number of Employees | 124 |
| Recent SEC Filing | 09/11/2019 4/A |
| President, Chief Executive Officer & Director | Robert B. Bazemore |
| Chief Financial Officer | Paolo Tombesi |
| Chief Medical Officer | Shefali Agarwal |
| Vice President-Business Development | Michael Boretti |
Company Highlights
| Price Open | $11.88 |
| Previous Close | $12.19 |
| 52 Week Range | $5.14 - 16.59 |
| Market Capitalization | $1.1 B |
| Shares Outstanding | 91.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 11/01/2019 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | N/A |
| Earnings per Share | -$1.75 |
| Beta vs. S&P 500 | N/A |
| Revenue | $21.7 M |
| Net Profit Margin | -588.48% |
| Return on Equity | -50.32% |
Analyst Ratings as of 09/05/2019
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |